Firkin F C, Maher D
University of Melbourne, Department of Medicine, Victoria, Australia.
Eur J Haematol. 1988 Sep;41(3):212-7. doi: 10.1111/j.1600-0609.1988.tb01183.x.
Remissions occurred in 2 of 5 consecutive cases of acquired pure red cell aplasia (PRCA) during an initial course of treatment with either azathioprine and prednisolone, or cyclophosphamide and prednisolone. Crossover to therapy with the alternative cytotoxic immunosuppressive agent in conjunction with continued administration of prednisolone in 3 unresponsive cases resulted in remission induction. Crossover to azathioprine was effective in 2 cases initially unresponsive to cyclophosphamide, and crossover to cyclophosphamide in 1 initially unresponsive to azathioprine. This emphasises that lack of cross-resistance to these drugs can occur in PRCA, and that crossover to treatment with the alternative agent in refractory cases is a useful strategy which has been underutilised in reported approaches to management. Administration of the effective regimen was continued for a mean of 15 months, and this more extended period of treatment was associated with a longer mean duration of remission than reported in previous studies.
在最初使用硫唑嘌呤和泼尼松龙或环磷酰胺和泼尼松龙治疗的5例连续获得性纯红细胞再生障碍性贫血(PRCA)病例中,有2例出现缓解。在3例无反应的病例中,交叉使用另一种细胞毒性免疫抑制剂并继续给予泼尼松龙治疗导致缓解诱导。交叉使用硫唑嘌呤对最初对环磷酰胺无反应的2例有效,交叉使用环磷酰胺对最初对硫唑嘌呤无反应的1例有效。这强调了PRCA中可能存在对这些药物缺乏交叉耐药性的情况,并且在难治性病例中交叉使用另一种药物进行治疗是一种有用的策略,但在已报道的治疗方法中未得到充分利用。有效方案的给药平均持续15个月,与先前研究报道相比,这种更长时间的治疗与更长的平均缓解持续时间相关。